Leukapheresis device market to reach $1.01 billion by 2030

The leukapheresis device market is projected to grow from $0.7 billion in 2025 to $0.76 billion in 2026, with North America holding the largest share. The Business Research Company says rising blood disorders, automation, and portable systems will keep demand climbing through 2030.

Why it matters: - Leukapheresis devices are used to isolate white blood cells for treatments tied to leukemia, stem cell transplants, autoimmune disease care and research. - Demand is rising as blood-related disorders become more common and hospitals expand apheresis services. - The market is expected to keep growing as developers push portable, automated and point-of-care systems.

What happened: - The Business Research Company released its Leukapheresis Device Global Market Report 2026, covering market size, trends and a forecast through 2035. - The report puts the market at $0.7 billion in 2025 and $0.76 billion in 2026, a projected 8.6% CAGR in the near term. - The report forecasts the market will reach $1.01 billion by 2030, with a 7.4% CAGR over that period. - North America held the largest share of the global leukapheresis device market in 2025.

The details: - Leukapheresis devices use centrifugation or filtration to selectively collect leukocytes from blood drawn from patients or donors. - The devices support leukemia treatment, stem cell transplants, autoimmune disease management, clinical research and diagnostics. - Growth over the past period was driven by higher leukemia and autoimmune disease incidence, broader stem cell therapy use, better blood cell separation technology, more clinical research and more hospital-based apheresis services. - Future growth is expected to come from portable leukapheresis devices, AI and automation features, biopharmaceutical research, regulatory approvals for new devices and precision medicine investment. - Emerging trends include personalized leukapheresis treatment, minimally invasive techniques, portable and point-of-care systems, real-time monitoring and more automation to improve workflow efficiency. - The report also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The Business Research Company says the 2026 report adds market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, market hotspot infographics, key technology analysis and updated graphics and tables. - The report offers a free sample here. - The full report is available here.

Between the lines: - The forecast suggests leukapheresis is moving from a niche blood-processing tool toward a broader platform for specialized care and research. - North America's lead likely reflects deeper healthcare infrastructure and established access to advanced blood-treatment services. - The strongest growth signals point to devices that are easier to deploy, more automated and better suited to outpatient or point-of-care settings.

What's next: - The market is expected to add more share through 2030 if adoption of portable and automated systems accelerates. - Asia-Pacific is positioned for faster expansion as healthcare infrastructure improves and blood-disease prevalence rises. - Further gains will likely depend on new device approvals, investment in precision medicine and broader clinical use.